reports
- Kate Heseltine
Cannabics Pharmaceuticals - Developing cannabinoid-based therapies
Cannabics develops cannabinoid-based, tumour reducing therapies. Its bioinformatics platform evaluates the efficacy of thousands of cannabinoid compounds on various cancers. In addition, it has recently launched a psychedelic inspired research programme focused on neuropsychiatric disorders. Its most advanced therapies target the $18bn colorectal cancer market, with human clinical trials planned to commence in 2022. Earlier-stage therapies target breast cancer, prostate cancer and melanomas. Can...
- Kate Heseltine
Cannabics Pharmaceuticals - Developing cannabinoid-based therapies
Cannabics develops cannabinoid-based, tumour reducing therapies. Its bioinformatics platform evaluates the efficacy of thousands of cannabinoid compounds on various cancers. In addition, it has recently launched a psychedelic inspired research programme focused on neuropsychiatric disorders. Its most advanced therapies target the $18bn colorectal cancer market, with human clinical trials planned to commence in 2022. Earlier-stage therapies target breast cancer, prostate cancer and melanomas. Can...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.